Weekly FDA Enforcement Roundup — March 6–13, 2026
13 warning letters. A new draft guidance on 483 responses. 61 drug approvals pulled. The AEMS launch. And Novo Nordisk in the hot seat over unreported GLP-1 deaths.
Weekly FDA Enforcement Roundup — March 6–13, 2026
13 warning letters. A new draft guidance on 483 responses. 61 drug approvals pulled. The AEMS launch. And Novo Nordisk in the hot seat over unreported GLP-1 deaths.
This was a busy week. Here is what matters.
1. Novo Nordisk cited for unreported deaths on Ozempic and Wegovy
The FDA issued warning letter MARCS-CMS 717576 to Novo Nordisk following a January-February 2025 inspection of their Plainsboro, NJ site. The core finding: Novo failed to report serious adverse drug experiences within the mandatory 15-calendar-day window under 21 CFR 314.80(b).
Three deaths went unreported on time, including one suicide. At least 10 serious adverse events were never filed as individual case safety reports. One patient was disabled after a stroke while on liraglutide. Novo's internal procedures required reporter consent before following up on adverse events, which meant cases fell through the cracks when reporters didn't respond.
Novo has hired a consultant to review its pharmacovigilance systems and is auditing all closed PV deviations back to June 2017. The FDA called the response "inadequate" and gave the company 15 days to provide a more detailed corrective plan.
This is the third FDA admonishment for Novo in recent weeks. The signal is clear: pharmacovigilance for GLP-1 products is now a priority enforcement area. Companies with marketed GLP-1 or weight-management products should audit their 15-day reporting pipelines now, not after an inspection.
2. FDA publishes first-ever draft guidance on responding to Form 483 observations
On March 6, the FDA released a draft guidance titled "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection" (Docket FDA-2025-D-1504). This is the first time the agency has codified its expectations for how drug manufacturers should respond to 483s.
The key points:
Respond within 15 business days. Late responses may not delay regulatory action, including a warning letter. Send one complete response, not piecemeal submissions. The response should be signed by someone in executive management with the authority to allocate resources. Include a root cause analysis, a corrective and preventive action (CAPA) plan, and a risk assessment covering the effect on safety, identity, strength, quality, and purity. If you disagree with an observation, say so with supporting evidence, but do it in the response, not informally during the inspection.
The comment period closes May 8, 2026.
If you manufacture drugs, biologics, or animal drugs in the US or abroad, this guidance is the new baseline for your 483 response playbook. Update your SOPs before the final version drops.
3. AEMS goes live, replacing FAERS and VAERS
On March 11, the FDA launched the Adverse Event Monitoring System (AEMS), a single platform that replaces seven legacy adverse event databases. FAERS (drugs and biologics) and VAERS (vaccines) are the first to migrate. Device, food, supplement, and tobacco reporting systems follow in May.
The practical change: adverse event reports are now published in real time instead of quarterly. The platform uses AI-based redaction and digitization to speed processing. A public dashboard lets anyone query the data.
The FDA previously spent approximately $37 million per year operating those seven databases and processed about 6 million reports annually. AEMS is projected to save $120 million over five years.
For regulated companies, the compressed reporting timeline means your pharmacovigilance teams will see their own reports reflected publicly faster. It also means competitors, journalists, and class-action attorneys will see them faster. Review your signal detection workflows accordingly.
4. 61 drug approvals withdrawn (Watson Labs + Aspen Global)
Two Federal Register notices this week pulled a combined 61 approved drug applications. Watson Laboratories had 15 ANDAs withdrawn (effective April 13, 2026). Aspen Global Inc., via Lachman Consultant Services, had 46 NDAs withdrawn.
Both sets of withdrawals were at the applicants' request because the products are no longer marketed. This is routine housekeeping, not enforcement. But it matters for companies tracking reference listed drugs, generic competition, or supply continuity. If any of these 61 products are in your supply chain, confirm your alternatives are still approved and available.
5. Pharma CGMP warning letter cluster (3 letters, same day)
Three pharma CGMP warning letters all posted March 10, all issued March 3:
Fareva Morton Grove (Morton Grove, IL). French-owned contract manufacturer for OTC drugs. CGMP violations at their Illinois facility following an August 2025 inspection. The FDA reviewed and rejected their September 2025 483 response.
Simtra BioPharma Solutions (formerly Baxter Oncology GmbH, Halle/Westphalia, Germany). Unannounced September 2025 inspection found CGMP violations in their finished pharma operations. Their October 2025 response was deemed insufficient.
Tentamus India Private Limited (Hyderabad, India). Contract testing laboratory. CGMP violations found during an August 2025 inspection, with an additional finding that Tentamus "delayed or limited access to records requested" by investigators. Obstructing an inspection is a separate, serious violation.
The pattern: FDA conducted inspections in mid-2025, received responses it considered inadequate, and issued three warning letters on the same day. Contract manufacturers and testing labs should note that the FDA treats access delays as their own violation category, separate from the underlying CGMP findings.
6. Nu Skin cited for drug listing violations
The FDA issued warning letter MARCS-CMS 722667 to NSE Products (Nu Skin Enterprises) in Provo, UT. The violation: Nu Skin failed to meet its drug listing obligations under Section 510(j) of the FD&C Act for three AP-24 dental products (Fluoride, AP-24, and Whitening).
Under 21 CFR 207, drug registrants must review and update their listing information every June and December. Nu Skin did not. Drug listing violations are straightforward to fix but carry real consequences: products from non-compliant registrants can be flagged for detention at import.
Companies that sell OTC drugs, cosmetics classified as drugs (like fluoride toothpaste), or any product requiring drug registration should add a calendar reminder for the semi-annual listing review. The FDA is clearly enforcing this requirement.
7. Tobacco enforcement continues (4 warning letters)
Four warning letters went to tobacco retailers and online vendors for violations of the Family Smoking Prevention and Tobacco Control Act: idripejuice.com, thesnuslife.com, snushaven.com, and SSS AUSTAR LLC. All cited for selling adulterated and misbranded tobacco products.
This continues the enforcement pattern that started in January. If you sell nicotine pouches, ENDS, or vape products without premarket authorization, the FDA is actively sending letters.
8. Other notable actions this week
Biosimilar development. The FDA issued updated draft Q&As on biosimilar development under the BPCI Act, aiming to cut development costs and timelines. Press release on March 9.
Flavored ENDS guidance. A new draft guidance addresses youth risk considerations for flavored electronic nicotine delivery systems premarket applications. Published March 11.
Lidl recall. Lidl US issued an allergy alert for undeclared hazelnuts in Favorina Chocolate Ladybugs (March 12).
Erbe USA safety alert. An early alert flagged a flexible cryoprobe issue from Erbe USA (March 10).
Opioid disposal RFI. The FDA opened a public docket seeking comments on specifications for in-home disposal systems for outpatient opioid analgesics.
Drug importation. The FDA held a meeting with states on importing lower-cost drugs from abroad (March 6).
What to do this week
If you have pharmacovigilance obligations: Audit your 15-day reporting timeline. The Novo Nordisk letter shows the FDA is testing whether your PV system actually works under real conditions.
If you rely on FAERS or VAERS data: Switch to AEMS. The legacy systems are being retired. Plan for real-time data in your signal detection workflows.
If you have drug registrations: Confirm your listing is current in eDRLS. The Nu Skin letter is a reminder that semi-annual updates are not optional.
Policy Canary monitors FDA enforcement actions daily and flags what matters for your specific product categories. Start a free pilot to see what you're missing.
Get this in your inbox every Friday.
Free FDA intelligence digest. No account required.
